Zogenix

Zogenix is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of epilepsy and mitochondrial diseases. Read more

517 Followers on Owler
517 Followers on Owler
517 Followers on Owler
517 Followers on Owler

Zogenix

Zogenix is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of epilepsy and mitochondrial diseases. Read more

Stephen J. Farr's photo - President & CEO of Zogenix

President & CEO

Stephen J. Farr

CEO Approval Rating

81/100

Founded:

2006

Status:

PublicIndependent CompanyNASDAQZGNX

ZOGENIX TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Reneo is the biggest rival of Zogenix. Reneo was founded in 2014, and its headquarters is in San Diego, California. Reneo operates in the Pharmaceuticals industry. Reneo has 67 fewer employees than Zogenix.

PTC Therapeutics has been one of Zogenix's top competitors. PTC Therapeutics is a Public company that was founded in South Plainfield, New Jersey in 1998. PTC Therapeutics is in the Pharmaceuticals industry. PTC Therapeutics has 869 more employees vs. Zogenix.

Reata is Zogenix's #3 rival. Reata was founded in 2002 in Plano, Texas. Reata is in the Pharmaceuticals field. Reata generates $4.6M less revenue than Zogenix.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is CohBar a competitor of Zogenix?

Zogenix Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$13.6M

Zogenix's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 426.7M. Over the last four quarters, Zogenix's revenue has grown by 580.7%. Specifically, in Q4 2020's revenue was $8.5M; in Q3 2020, it was $2.9M; in Q2 2020, it was $1M; in Q1 2020, Zogenix's revenue was $1.2M.

Zogenix Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Modis Therapeutics, Inc.

Aug 2019

Source »
$250M
Modis Therapeutics is a biopharmaceutical company that develops and commercializes deoxynucleoside therapies for the treatment of genetic diseases.

These are all the companies that Zogenix has acquired. Zogenix's latest acquisition was Modis Therapeutics, Inc. in Aug 2019. Modis Therapeutics is a biopharmaceutical company that develops and commercializes deoxynucleoside therapies for the treatment of genetic diseases.

Zogenix Funding History

Since Zogenix was founded in 2006, it has participated in 11 rounds of funding. In total Zogenix has raised $494.3M. Zogenix's last funding round was on Oct 2020 for a total of $30.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Oct 2020
$30M
-
Debt
Sep 2020
$200M
-
IPO
Nov 2010
$56M
-
Debt
Jul 2010
$35M
Equity
Jun 2010
$15M

Since Zogenix was founded in 2006, it has participated in 11 rounds of funding. In total Zogenix has raised $494.3M. Zogenix's last funding round was on Oct 2020 for a total of $30.0M

Zogenix Investments

No recent investments found related to Zogenix

These are all the companies that Zogenix has invested in. Zogenix's latest investment was Modis Therapeutics, Inc. in Aug 2019. Modis Therapeutics is a biopharmaceutical company that develops and commercializes deoxynucleoside therapies for the treatment of genetic diseases.

Zogenix News

January 11, 2021BioSpace

Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net Product Sales

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare diseas... See more »
December 23, 2020Pharmafile

Zogenix gets EU marketing authorisation for anti-seizure drug

The European Commission (EC) has granted marketing authorisation for Zogenix's FINTEPLA (fenfluramine... See more »
December 5, 2020Pharmabiz

Tevard Biosciences, Zogenix collaborate to identify and develop novel tRNAbased gene therapies for Dravet syndrome and other genetic epilepsies

Tevard Biosciences, a privately─held biotechnology company pioneering tRNA─based gene therapies, and ... See more »

Zogenix Press Releases

March 25, 2021GlobeNewswire

Zogenix to Participate in the Stifel 3rd Annual CNS Day

EMERYVILLE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceut... See more »
March 2, 2021GlobeNewswire

Zogenix to Participate in the Raymond James Institutional Investors Conference

EMERYVILLE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceut... See more »
February 25, 2021GlobeNewswire

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

EMERYVILLE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceuti... See more »
February 18, 2021GlobeNewswire

Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

EMERYVILLE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceuti... See more »
February 1, 2021StreetInsider

Zogenix's FINTEPLA (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet Syndrome

FINTEPLA offers a new treatment option for patients in Germany with Dravet syndrome, a rare, devastat... See more »
December 21, 2020GlobalNewswire

The European Commission Approves Zogenix's FINTEPLA (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome

EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceuti... See more »
December 1, 2020GlobeNewswire

Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020

EMERYVILLE, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceuti... See more »

Social Media

Zogenix Headquarters

12400 High Bluff Drive Suite 650

San Diego, California92130

1-866-964-3649

Driving Directions »

Trending Companies

Zogenix Summary

ABOUT

Overview

Zogenix is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of epilepsy and mitochondrial diseases. Zogenix was founded in 2006. Zogenix's headquarters is located in San Diego, California, USA 92130. It has r...

CEO

Zogenix's President & CEO, Stephen J. Farr, currently has an approval rating of 81%. Zogenix's primary competitors are Reneo, PTC Therapeutics & Reata.

Website

zogenix.com

Frequently Asked Questions about Zogenix

  1. When was Zogenix founded?

    Zogenix was founded in 2006
  2. Who is Zogenix's CEO?

    Zogenix's CEO is Stephen J. Farr
  3. How much revenue does Zogenix generate?

    Zogenix generates $13.6M in revenue
  4. How much funding does Zogenix have?

    Zogenix has historically raised $494.3M in funding
  1. Where is Zogenix's headquarters?

    Zogenix's headquarters is in San Diego California, USA
  2. How many employees does Zogenix have?

    Zogenix has 90 employees
  3. What sector does Zogenix operate in?

    Zogenix is in Pharmaceuticals, Biotechnology
  4. Who are Zogenix's competitors?

    Zogenix's top competitors are Reneo, PTC Therapeutics, Reata